LaSOM335, active against bladder cancer cells, interferes withLet‐60(hRas) and reducesCD73 expression/activity
Authors:
- Luciano Porto KagamiLKLuciano Porto Kagami
- Itamar Luís GonçalvesItamar Luís Gonçalves
- Gustavo Machado das NevesGNGustavo Machado das Neves
- Fabrício FigueiróFFFabrício Figueiró
- Solange Cristina GarciaSGSolange Cristina Garcia
- Daiana Silva ÁvilaDaiana Silva Ávila
- Ana Maria Oliveira BattastiniABAna Maria Oliveira Battastini
- 5 June 2023
- journal article
- research article
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 102 (3) , 536-546
Abstract
Bladder cancer is the fourth most common malignancy in men. It can present along the entire continuum of severity, from mild to well‐differentiated disease to extremely malignant tumors with low survival rates. HumanRASgenes are the most frequently mutated oncogenes in human cancers, and the critical role of aberrant Ras protein function in carcinogenesis is well established. Therefore, considerable efforts have been devoted to the development of anti‐Ras inhibitors for cancer treatment. This study presents the biphenyl dihydropyrimidinone LaSOM 335 with high activity against T24 bladder cancer cells (IC50 = 10.73 ± 0.53 μM) and selectivity of cytotoxicity for this cancer cell line compared to two non‐cancer cell lines investigated. Furthermore, we also show that this compound reduced vulvar development in the mutantlet‐60 gene ofCaenorhabditis elegans.Let‐60 is a homolog of the mammalian Ras gene. In addition, we observed that LaSOM 335 inhibits the enzymatic activity of CD73 and decreases CD73 expression. Possibly, this expression decrease is due to downstream EGFR signaling via the Ras–Raf–ERK pathway, that directly regulates CD73 expression via ERK1/2. Evidence suggests that non‐immunomodulating functions of CD73 play an equally important role for cancer cell survival, progression, and migration. Regarding we also notice that LaSOM 335 was safe in the in vivo model ofC. elegans. The set of these findings makes this biphenyl dihydropyrimidinone a promising candidate for further investigations in the bladder cancer field.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
This publication has 30 references indexed in Scilit:
- Pre-clinical pharmacokinetics and acute toxicological evaluation of a monastrol derivative anticancer candidate LaSOM 65 in ratsXenobiotica, 2013
- Crystal Structure of the Human Ecto-5′-Nucleotidase (CD73): Insights into the Regulation of Purinergic SignalingStructure, 2012
- Caenorhabditis elegans as a Model in Developmental Toxicology2012
- Synthesis of dihydropyrimidin-2-one/thione library and cytotoxic activity against the human U138-MG and Rat C6 glioma cell linesJournal of the Brazilian Chemical Society, 2011
- Differential ectonucleotidase expression in human bladder cancer cell linesUrologic Oncology: Seminars and Original Investigations, 2010
- Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatasesCellular Signalling, 2008
- Indomethacin stimulates activity and expression of ecto-5′-nucleotidase/CD73 in glioma cell linesEuropean Journal of Pharmacology, 2007
- Genetic analysis of ETS genes in C. elegansOncogene, 2000
- A direct colorimetric assay for Ca2+-stimulated ATPase activityAnalytical Biochemistry, 1986
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976